Eliem Therapeutics, Inc. Reports Q1 2023 Net Loss of $22.3 Million
Q1 2023 Revenue for Eliem Therapeutics, Inc. Stands at $1.15 Million
By USInMinutes
Published - Jul 20, 2023, 08:59 AM ET
Last Updated - Jul 20, 2023, 08:59 AM EDT
Eliem Therapeutics, Inc.(ELYM), a leading pharmaceutical compa ny, has released its unaudited Condensed Consolidated Financial Statements for the first quarter of 2023. The company reported a net loss of $22.3 million during this period. Alongside the net loss, Eliem Therapeutics also disclosed its revenue for Q1 2023, which stood at $1.15 million.
Net Income/Loss
The financial report unveiled that Eliem Therapeutics, Inc. experienced a net loss of $22.3 million for the three months ended March 31, 2023. This represents a significant financial challenge for the company during the mentioned quarter.
Revenue
